PURPOSE OF REVIEW: This review encompasses the recently published information on clonal hematopoiesis of indeterminate potential (CHIP) and discusses its future prospects. By announcing advances in the research of CHIP risk factors and related diseases, with the purpose of offering new insights to treat both hematologic and nonhematologic disorders. RECENT FINDINGS: The majority of studies have shown that CHIP is a common biological condition associated with aging and the incidence of clonal hematopoiesis increases with age. The pathophysiology of blood diseases is projected to be significantly influenced by CHIP. Nevertheless, increasing studies have expanded the application of CHIP to cover nonhematologic diseases such as cardiovascular, renal, liver, and pulmonary diseases. Furthermore, with the fast advancement of genetic testing technology and preventive medicine, the involvement of CHIP in a variety of disorders shows promise as an essential target for preventing disease onset and progression. SUMMARY: CHIP is linked to a variety of illnesses and has a significant influence on an individual's health outlook. Thus, identifying and managing CHIP is critical for improving the clinical results of the individuals concerned.